Institute of Pharmacy and Molecular Biotechnology
Research at the IPMB is focussed on the development, investigation, and application of drugs and bioactive compounds, as well as on the elucidation of molecular and cellular mechanisms of action. This research integrates experimental approaches of chemistry, molecular and cellular biology, pharmacology, bioinformatics, and pharmaceutics. Main research areas of our institute include nucleic acids as tools and drug targets, development of new antiinfective drugs, molecular evolution & proteomics, research on neurodegenerative diseases, systems biology as well as drug targeting and transport.
Neurobiology of Peptides: Publication in PNAS
Peptides designed and first prepared in the IPMB Medicinal Chemistry department were shown by co-workers from the IZN (Mauceri, Bading, et al.) to protect the neuronal architecture after cerebral stroke, as published in the Proceedings of the National Academy of Sciences (PNAS) and highlighted on the University website.
ERC Advanced Grant at the IPMB!
The Institute is happy and proud to congratulate Prof. Dr. Andres Jäschke for his success at the European Research Council: He was awarded a 2.5 million Euro ERC Advanced Grant. Please see the press release of Heidelberg University (in German).
Automatic Motion Analysis of HIV Particles – Publication in „Nature Communications“
The research group of PD Dr. Karl Rohr has developed a new computer-based method for motion analysis of HIV (Human Immunodeficiency Virus) particles. With this method the spread of HIV under different tissue conditions was quantified. The work was published in the journal Nature Communications.
IPMB has IM2PACT
The Department of Pharmaceutical Technology and Biopharmacy (Prof. Fricker) is member of the new consortium IM2PACT of 27 international partners from academia, industry, and small and medium enterprises, which aims to tackle the unmet challenge of discovery and characterization of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics. The funding of 18 million Euro from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest public private partnership and is funded jointly by the European Union´s Horizon 2020 research and innovation programme and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
IZN Young Investigator Award for MoBi alumnus
Max Richter was awarded this year's Chica and Heinz Schaller Young Investigator Award for his work on the molecular basis of Alzheimer's disease. His work uncovered „Distinct in vivo roles of secreted APP ectodomain variants APPsa and APPsb in regulation of spine density, synaptic plasticity, and cognition“ and was featured in the April 2018 Cover of the EMBO-Journal. Max is a Alumnus of our prestigious Program in Molecular Biotechnology and will finish his PhD in the group of Prof. Müller later this year. Congratulation!
Double success for HEIDELTEC
Twice successfully: The Team of HEIDELTEC, being located within the Institute of Pharmacy and Molecular Biotechnology (IPMB) was ranked 3rd place in the “Gründerpreis Baden-Württemberg 2018”, which was endowed with 5000,- Euro. In addition, the team won the ACHEMA-Gründerpreis 2018 (10.000,- Euro). Subject of research and development of HEIDELTEC (Dr. Silvia Pantze, Dr. Robin Tremmel, Dr. Frieder Helm und Moritz Stadler) is the creation of a solid oral dosage form for peptides and proteins, drug which otherwise can only be applied by intravenous injections. More about it in this video.
Receptor for the APP fragment APPsα discovered: publication in "The EMBO Journal"
A cleavage product of the Alzheimer's Amyloid precursor protein APP stimulates, synapse density, synaptic plasticity and memory. The secreted ectodomain of APP, known as APPsα, acts as a soluble signalling molecule on other nerve cells. A research team led by Prof. Ulrike Müller gained new insights into the molecular mechanism underlying its physiological functions and discovered a receptor for APPsα. The work was published in "The EMBO Journal“ publiziert. For more information, please refer to the website of Heidelberg university.
Computer-based Analysis of Bacteria – Publication in „Nature Communications“
The research group of PD Dr. Karl Rohr has developed a new automatic method for analyzing live cell microscopy images of bacteria. The method was used to investigate different nutrient conditions to study the role of memory in the B. subtilis life cycle. The work was published in the journal Nature Communications
Automatic Cell Tracking in Microscopy Images – Publication in „Nature Methods“
HeiDelTec on the route to success
Heidelberg Delivery Technologies, HeiDelTec GmbH, a new start-up com-pany arose from the Institute of Pharmacy and Molecular Biotechnology. After successful participation in the Exist-Research-Transfer Program of the BMWi the IPMB leads basic pharmaceutical research to practical ap-plication thus setting new pulses in the area of improving bioavailability and effectiveness of drug formulations. For further Information, follow this link.
Structure and Function of the first bacterial decapping enzyme: Publication in "Nature Chemical Biology"
Structure of Zika virus protease and inhibitor: Publication in "Science"
The group of Prof. Christian Klein co-authored a publication in "Science"that describes the three-dimensional structure of the Zika virus protease. This enzyme is a target protein for the discovery of antiviral drugs against Zika and related, emerging pathogens such as dengue and West Nile virus. See also: "Zika-Virus: Struktur eines Schlüsselenzyms aufgeklärt."
Protein Repairs Nerve Cell Damage